Search Results for: "Clinic Roundup"
-
Clinic Roundup
The primary endpoint is change in quality of life and physical functioning, including the six-minute walk test, body weight, Kansas City Cardiomyopahty Questionnaire, NT-pro BNP and time to first heart failure hospitalization, decongestion therapy or deathBioWorld Today | Friday, April 12, 2013 -
Clinic Roundup
There was also a trend toward improvement in quality of life compared to placeboBioWorld Today | Friday, April 5, 2013 -
Clinic Roundup
Patient Generated Subjective Global Assessment scores also demonstrated improvement (p = 0.025), suggesting enhanced quality of lifeBioWorld Today | Friday, March 22, 2013 -
Clinic Roundup
Patients will be followed for a minimum of two years with respect to safety, brain imaging and measures of cognitive function and quality of lifeBioWorld Today | Thursday, March 14, 2013 -
Clinic Roundup
The study is designed to demonstrate a reversal of weight loss following treatment with MT-102, but also will examine improvement in functional ability and quality of life by a battery of previously validated instrumentsBioWorld Today | Tuesday, March 5, 2013 -
Clinic Roundup
The objectives are to measure progression-free survival and overall survival, while safety parameters, quality-of-life impact, manufacturing quality and additional laboratory assessments also will be investigatedBioWorld Today | Friday, March 1, 2013 -
Clinic Roundup
The 12-month trial will measure improvement in visual function as the primary endpoint, with secondary outcome measurements assessing neurologic and neuromuscular function, glutathione biomarkers, quality of life and safetyBioWorld Today | Wednesday, February 20, 2013 -
Clinic Roundup
Secondary endpoints are hemodynamic and quality-of-life measurementsBioWorld Today | Wednesday, January 16, 2013 -
Clinic Roundup
The trial also will evaluate spontaneous bowel movements, daily abdominal pain, discomfort and bloating scores as well as the impact of plecanatide on disease-specific quality-of-life measuresBioWorld Today | Friday, December 28, 2012 -
Clinic Roundup
The primary endpoint is the normalized number of angioedema attacks recorded during each treatment period, while secondary endpoints will assess attack severity, quality-of-life parameters and number of angioedema attacks requiring acute treatmentBioWorld Today | Thursday, December 20, 2012 -
Clinic Roundup
The study will evaluate the effects of once-daily dosing of AC-1204 for 26 weeks on cognition, pharmacokinetic measures, activities of daily living, resource utilization and quality of life among subjects with mild-to-moderate AD with a primary endpoint tagged to the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale after 26 weeks among both carriers and noncarriers of the epsilon 4 variant of the gene apolipoprotein EBioWorld Today | Tuesday, November 27, 2012 -
Clinic Roundup
That study will explore TSC's effects on tumor regrowth, patient quality of life and overall survival in GBM patients when dosed in conjunction with conventional radiation therapyBioWorld Today | Tuesday, November 20, 2012 -
Clinic Roundup
Immunomedics Inc., of Morris Plains, N.J., said patients receiving epratuzumab reported clinically meaningful improvements in health-related quality of life (HRQoL) that were sustained over about four years of treatmentBioWorld Today | Wednesday, November 14, 2012 -
Clinic Roundup
The primary objective is to compare the drug to placebo over a one-year treatment period, with quality of life as a secondary objectiveBioWorld Today | Thursday, November 1, 2012 -
Clinic Roundup
Secondary endpoints include safety, overall survival, complete hematologic response CR, progression-free survival, duration of response and quality of lifeBioWorld Today | Monday, October 22, 2012 -
Clinic Roundup
A second poster will present data indicating that patients who responded to treatment significantly increased three separate measures of quality of life, regardless of ageBioWorld Today | Tuesday, October 9, 2012 -
Pharma: Clinic Roundup
Started in March, the Eslicarbazepine acetate in Partial-Onset Seizures study is intended to enroll about 800 patients, with a primary endpoint of six-month retention rate and other assessments, including seizure frequency, adverse events and quality of lifeBioWorld Today | Thursday, October 4, 2012 -
Pharma: Clinic Roundup
Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, reported new patient-reported health-related outcomes for its investigational oncology compound afatinib, including lung cancer-related symptoms and quality of lifeBioWorld Today | Monday, October 1, 2012 -
Pharma: Clinic Roundup
The primary endpoint is the annual rate of decline in forced vital capacity, while secondary endpoints include health-related quality of life, exacerbations, respiratory mortality, overall survival and on-treatment survivalBioWorld Today | Thursday, September 27, 2012 -
Pharma: Clinic Roundup
Secondary endpoints include change from baseline in quality of life, time to first acute exacerbation, respiratory mortality, overall survival and on-treatment survivalBioWorld Today | Tuesday, September 25, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.